MiNK Therapeutics (INKT) Cash from Financing Activities (2020 - 2026)

MiNK Therapeutics has reported Cash from Financing Activities for 7 years, with the latest figure at -$2.1 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 364827.43% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.6 million (up 117.08% YoY) and the FY2025 annual result came in at $14.7 million, up 36.06% from the prior year.
• Cash from Financing Activities retreated to -$2.1 million in Q1 2026 per INKT's latest filing, from $1.2 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $13.5 million in Q3 2025 and troughed at -$2.1 million in Q1 2026.
• A 5-year average of $1.3 million and a median of $540.0 in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities surged 39170200.0% in 2025, then slumped 364827.43% in 2026.
• Over 5 years, Cash from Financing Activities stood at $111.0 in 2022, then sank by 101.8% to -$2.0 in 2023, then slumped by 50.0% to -$3.0 in 2024, then soared by 39170200.0% to $1.2 million in 2025, then slumped by 278.78% to -$2.1 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$2.1 million, $1.2 million, and $13.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.